{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:40:17Z","timestamp":1756294817648,"version":"3.44.0"},"reference-count":14,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,3,26]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>Abatacept is a biological agent that modulates T-cell costimulation by blocking CD28 signalling. This cytotoxic T-lymphocyte-associated antigen-4-Ig fusion protein was approved for treatment of rheumatoid arthritis (RA). However, a few case reports have revealed respiratory failure after abatacept treatment. In this report, we present a patient with RA who developed severe acute respiratory distress syndrome (ARDS) and who passed away 2\u2009months after starting abatacept. A comprehensive analysis including radiology, blood examinations, infectious panel and flow cytometry lymphocyte analysis was done to determine the cause of respiratory failure. Since no infection was detected in this patient, an association between ARDS and abatacept is a strong possibility due to significant adverse reactions to the biological agent. Considering the rapid progression of respiratory failure after abatacept treatment in this report, we suggest that pulmonary function testing and lung structure evaluation be regarded throughout the early stage of treatment of patients with RA.<\/jats:p>","DOI":"10.1136\/bcr-2019-231725","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T05:54:20Z","timestamp":1586238860000},"page":"e231725","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Rapid development of severe acute respiratory distress syndrome after abatacept treatment in a patient with rheumatoid arthritis"],"prefix":"10.1136","volume":"13","author":[{"given":"Jorge","family":"Gower","sequence":"first","affiliation":[{"name":"Molecular and Translational Immunology Laboratory, Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, Universidad de Concepcion, Concepcion, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0069-3420","authenticated-orcid":false,"given":"Gonzalo","family":"Labarca","sequence":"additional","affiliation":[{"name":"Molecular and Translational Immunology Laboratory, Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, Universidad de Concepcion, Concepcion, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Enos","sequence":"additional","affiliation":[{"name":"Internal Medicine, Universidad San Sebastian, Los Angeles, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estefania","family":"Nova-Lamperti","sequence":"additional","affiliation":[{"name":"Molecular and Translational Immunology Laboratory, Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, Universidad de Concepcion, Concepcion, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"2025082704041741000_13.4.e231725.1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"The Lancet"},{"key":"2025082704041741000_13.4.e231725.2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1371542"},{"key":"2025082704041741000_13.4.e231725.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.27405"},{"key":"2025082704041741000_13.4.e231725.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211138"},{"key":"2025082704041741000_13.4.e231725.5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients","volume":"48","author":"Fern\u00e1ndez-D\u00edaz","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025082704041741000_13.4.e231725.6","doi-asserted-by":"publisher","DOI":"10.2177\/jsci.35.433"},{"key":"2025082704041741000_13.4.e231725.7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5152\/eurjrheum.2015.0037","article-title":"A case of acute respiratory failure in a rheumatoid arthritis patient after the administration of abatacept","volume":"3","author":"Do\u011fu","year":"2016","journal-title":"Eur J Rheumatol"},{"key":"2025082704041741000_13.4.e231725.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.06.008"},{"key":"2025082704041741000_13.4.e231725.9","article-title":"Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: a cohort study","author":"Kang","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025082704041741000_13.4.e231725.10","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200205000-00005"},{"key":"2025082704041741000_13.4.e231725.11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1488-5","article-title":"Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting","volume":"20","author":"Alten","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025082704041741000_13.4.e231725.12","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22783"},{"key":"2025082704041741000_13.4.e231725.13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/1744666X.2018.1411190","article-title":"Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review","volume":"14","author":"Atzeni","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2025082704041741000_13.4.e231725.14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/RHU.0000000000000775","article-title":"Use of abatacept in Chilean patients with long-standing severe rheumatoid arthritis without previous use of biologics","volume":"25","author":"Valenzuela","year":"2019","journal-title":"J Clin Rheumatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-231725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:04:23Z","timestamp":1756292663000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-231725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,6]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/bcr-2019-231725"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-231725","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}